ABMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Abiomed's Enterprise Value is $16,360 Mil. Abiomed's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $254 Mil. Therefore, Abiomed's EV-to-EBIT for today is 64.38.
The historical rank and industry rank for Abiomed's EV-to-EBIT or its related term are showing as below:
During the past 13 years, the highest EV-to-EBIT of Abiomed was 694.68. The lowest was 22.03. And the median was 63.09.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Abiomed's Enterprise Value for the quarter that ended in Sep. 2022 was $10,277 Mil. Abiomed's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $254 Mil. Abiomed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was 2.47%.
The historical data trend for Abiomed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abiomed Annual Data | |||||||||||||||||||||
Trend | Mar13 | Mar14 | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | 79.87 | 55.13 | 24.44 | 60.31 | 55.81 |
Abiomed Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
EV-to-EBIT | Get a 7-Day Free Trial | 54.29 | 61.60 | 55.81 | 40.67 | 40.44 |
For the Medical Devices subindustry, Abiomed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Abiomed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Abiomed's EV-to-EBIT falls into.
Abiomed's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 16360.271 | / | 254.109 | |
= | 64.38 |
Abiomed's current Enterprise Value is $16,360 Mil.
Abiomed's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $254 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abiomed (NAS:ABMD) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Abiomed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) | = | EBIT | / | Enterprise Value (Q: Sep. 2022 ) |
= | 254.109 | / | 10276.58152 | |
= | 2.47 % |
Abiomed's Enterprise Value for the quarter that ended in Sep. 2022 was $10,277 Mil.
Abiomed's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $254 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Abiomed's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Matthew T. Plano | officer: VP, GLOBAL OPERATIONS | C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923 |
Martin P Sutter | director | 2170 BUCKTHORNE PLACE, SUITE 170, THE WOODLAND TX 77380 |
David M Weber | officer: Chief Operating Officer | 2341 ROMANO CIRCLE, PLEASANTON CA 94566 |
Todd A Trapp | officer: Vice President, CFO | C/O WATTS WATER TECHNOLOGIES, INC., 815 CHESTNUT STREET, NORTH ANDOVER MA 01845 |
Michael R Minogue | director, officer: President & CEO | 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923 |
Paul Thomas | director | ONE MILLENNIUM WAY, BRANCHBURG NJ 08876 |
Paula A Johnson | director | 22 CHERRY HILL DRIVE, DANVERS MA 01923 |
Myron L Rolle | director | 1 NASHUA STREET, APARTMENT 1701, BOSTON MA 02114-1625 |
Dorothy E Puhy | director | DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115 |
Andrew J Greenfield | officer: VP Healthcare Solutions | 14 HILLSIDE DRIVE, GEORGETOWN MA 01833 |
Marc A Began | officer: VP & General Counsel | C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923 |
Michael G Howley | officer: Vice President | 22 CHERRY HILL DRIVE, DANVERS MA 01923 |
William J Bolt | officer: SVP, DA and QA | C/O ABIOMED INC, 22 CHERRY HILL DRIVE, DANVERS MA 01923 |
Rose Eric A Md | director | 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032 |
Henri A Termeer | director | ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
From GuruFocus
By Business Wire Business Wire • 12-05-2022
By PRNewswire PRNewswire • 11-01-2022
By PRNewswire PRNewswire • 11-15-2022
By GuruFocus Research GuruFocus Editor • 01-24-2023
By PRNewswire PRNewswire • 11-02-2022
By Business Wire Business Wire • 11-01-2022
By Business Wire Business Wire • 11-01-2022
By PRNewswire PRNewswire • 11-22-2022
By Business Wire Business Wire • 10-31-2022
By GuruFocus Research GuruFocus Editor • 02-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.